Nasdaq-listed Arvinas has hired Jared Freedberg as general counsel for the clinical-stage biotechnology company.
Freedberg was most recently general counsel at Intercept Pharmaceuticals, where he was responsible for managing all legal activities, including corporate and board governance, compliance, securities, contracting, intellectual property strategy and management, M&A, business development and litigation management.
Before that, he was general counsel and corporate secretary at Immunomedics. He had previously been general counsel for specialty generics and vice president for legal, business development and licensing at Mallinckrodt Pharmaceuticals.
According to his LinkedIn profile, Freedberg previously spent more than 15 years at Covance in positions including vice president for business development and strategy and earlier the dual role of vice president and associate general counsel and vice president for corporate development.
John Houston, Arvinas chair, CEO and president, says in a statement: ‘We are thrilled to welcome Jared to Arvinas. His extensive background in both legal and commercial functions will help provide a unique and invaluable perspective to our team. Jared’s wealth of experience will be instrumental in steering us through our first potential product commercialization while simultaneously helping to advance our pipeline of earlier stage assets.’
Freedberg says in announcing the move: ‘Arvinas is at the forefront of pioneering scientific advancements in protein degradation, and I am excited to support the company’s mission to improve the lives of patients with serious diseases.’
Ben Maiden
Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...
